AxoGen, Inc.
NASDAQ:AXGNMedical - Devices
+$0.25 today
- Market cap
- $3.40B
- Beta
- 1.12
- P/E (TTM)
- -73.4
- EPS (TTM)
- -$0.61
Volume 2.11M
Average 1.08M
AXGN Pre-Tax Margin
Income before tax as a percentage of revenue.
AxoGen, Inc.NASDAQ: AXGN
Pre-Tax Margin · Q3 FY2026 · quarter ended Sep 2026
Pre-tax margin widens to 3.1%
Pre-tax margin was 3.1% in Q3 FY2026, up 1.9 pp from a year earlier. On a trailing-twelve-month basis it was -12.0%, down 11.0 pp year over year. Over 3 fiscal years it widened by 13.9 pp.
Context
- Pre-tax margin widened in 2 of the last 3 fiscal years.
Sources:Income StatementText generated from reported figures; not investment advice.
Pre-Tax Margin history
Percent of revenue · from the income statement
- Latest · FY2025
- -7.0%
- Year-over-year change
- -1.7pp
| Period | Period end | Pre-Tax Margin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | -7.0% | -1.7pp |
| FY2024 | 2024-12-31 | -5.3% | +8.3pp |
| FY2023 | 2023-12-31 | -13.7% | +7.2pp |
| FY2022 | 2022-12-31 | -20.9% | +0.3pp |
| FY2021 | 2021-12-31 | -21.2% | — |
Pre-Tax Margin vs competitors
How AXGN compares with its peers on the latest reported figures
- AXGN's LTM Sep 2026 pre-tax margin of -12.0% is the 5th highest of the 7 companies compared; the peer median is 2.0%.
- Its year-over-year change of -11.0 pp is the 6th highest of 7, against a peer median of +4.6 pp.
- Over three fiscal years its change of +13.9 pp compares with a peer median of +21.5 pp.
| Company | Period | LTM level | YoY | 3-year change |
|---|---|---|---|---|
| LTM Jun 2026 | 39.2% | +31.7 pp | +102.6 pp | |
| LTM Mar 2026 | 10.9% | -4.6 pp | +23.2 pp | |
| LTM Mar 2026 | 3.2% | +12.9 pp | +19.7 pp | |
| LTM Mar 2026 | 0.8% | +6.1 pp | +3.8 pp | |
| LTM Sep 2026 | -12.0% | -11.0 pp | +13.9 pp | |
| LTM Jun 2026 | -51.2% | +3.0 pp | +58.9 pp | |
| LTM Mar 2026 | -4840.8% | -3838.0 pp | -1239.0 pp | |
| Peer median (excluding AXGN) | 2.0% | +4.6 pp | +21.5 pp | |
Competitors are the stored peer set for AXGN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 127.36M | 138.58M | 159.01M | 187.34M | 225.21M |
| Cost of Revenue | 22.93M | 29.78M | 37.14M | 45.36M | 57.86M |
| Gross Profit | 104.43M | 108.81M | 121.87M | 141.98M | 167.35M |
| Gross Margin | 82.0% | 78.5% | 76.6% | 75.8% | 74.3% |
| Research & Development | 24.18M | 25.63M | 27.34M | 27.77M | 32.89M |
| Selling, General & Admin | 105.67M | 112.89M | 115.99M | 117.5M | 142.32M |
| Operating Expenses | 129.84M | 138.52M | 143.33M | 145.26M | 175.2M |
| Depreciation & Amortization | 4.74M | 4.85M | 5.55M | 7.84M | 8.19M |
| EBITDA | (20.89M) | (23.47M) | (13.33M) | 6.08M | 192K |
| EBITDA Margin | -16.4% | -16.9% | -8.4% | 3.2% | 0.1% |
| Operating Income | (25.42M) | (29.71M) | (21.46M) | (3.29M) | (7.85M) |
| Operating Margin | -20.0% | -21.4% | -13.5% | -1.8% | -3.5% |
| Interest Income | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 1.36M | 624K | 2.84M | 8.21M | 7.7M |
| Other Income / Expenses | (1.57M) | 759K | (254K) | (6.68M) | (7.85M) |
| Income Before Tax | (26.99M) | (28.95M) | (21.72M) | (9.96M) | (15.7M) |
| Pre-Tax Margin | -21.2% | -20.9% | -13.7% | -5.3% | -7.0% |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (26.99M) | (28.95M) | (21.72M) | (9.96M) | (15.7M) |
| Net Margin | -21.2% | -20.9% | -13.7% | -5.3% | -7.0% |
| EPS (Basic) | (0.65) | (0.69) | (0.51) | (0.23) | (0.34) |
| EPS (Diluted) | (0.65) | (0.69) | (0.51) | (0.23) | (0.34) |
| Weighted Avg Shares | 41.22M | 42.08M | 42.88M | 44.26M | 46.05M |
| Weighted Avg Shares (Diluted) | 41.22M | 42.08M | 42.88M | 44.26M | 46.05M |
AxoGen, Inc.
NASDAQ:AXGN
Intrinsic Alpha fair value
Locked
Current Price
$56.95
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.